Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review

References

• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. 85(2): 177–189.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020. 6(1): 85.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10(8). 10.1186/1742-2094-10-8
   Google Scholar
• Jarius S, Wildemann B. The history of neuromyelitis optica. Part 2: ‘Spinal amaurosis,’ or how it all began. J Neuroinflammation. 2019;16(1):280.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004. 364(9451): 2106–2112.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473–477.
   PubMed Web of Science ®Google Scholar
• Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. London, UK: SAGE Publishing Ltd; 2011; Vol. 17, p. 1067–1073.
   Google Scholar
• Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665–669.
   PubMed Web of Science ®Google Scholar
• Li J, Bazzi SA, Schmitz F, et al. Molecular level characterization of circulating aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1034.
   PubMed Web of Science ®Google Scholar
• Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291(1–2):52–56.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23(6):661–683.
   PubMed Web of Science ®Google Scholar
• Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630–643.
   PubMed Web of Science ®Google Scholar
• Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617–629.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009;386(4):623–627.
   PubMed Web of Science ®Google Scholar
• Murata H, Kinoshita M, Yasumizu Y, et al. Cell-Free DNA derived from neutrophils triggers type 1 interferon signature in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1149.
   PubMed Web of Science ®Google Scholar
• Agasing AM, Wu Q, Khatri B, et al. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020;11(1):2856.
   PubMed Web of Science ®Google Scholar
• Graf J, Mares J, Barnett M, et al. Hans-Peter Hartung Neurol Neuroimmunol Neuroinflamm Jan. 2021;8(1):e919.
   PubMedGoogle Scholar
• Levy M, Wildemann B, Jarius S, et al. Chapter Six - immunopathogenesis of neuromyelitis optica. In: Frederick W. Alt, editors. Advances in Immunology. (Academic Press, 2014). 2014;213–242.
   Google Scholar
• Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–2094.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875–892.
   PubMed Web of Science ®Google Scholar
• Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762–772.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134.
   PubMedGoogle Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.
   PubMed Web of Science ®Google Scholar
• Borisow N, Mori M, Kuwabara S, et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol. 2018;9:888.
   PubMed Web of Science ®Google Scholar
• Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e62–e.
   PubMed Web of Science ®Google Scholar
• Banwell B, Bennett J, Marignier R, et al. Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): international MOGAD panel proposed criteria. Lancet Neurol. 2022. in press.
   Google Scholar
• Takai Y, Misu T, Suzuki H, et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. 2021;144(8):2401–2415.
   PubMedGoogle Scholar
• Akaishi T, Takahashi T, Misu T, et al. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep. 2020;10(1):13890.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834–1849.
   PubMedGoogle Scholar
• Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197–1204.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(14). 10.1186/1742-2094-9-14.
   PubMedGoogle Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16.
   PubMed Web of Science ®Google Scholar
• Holmøy T, Høglund RA, Illes Z, et al. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. 2021;268(12):4522–4536.
   PubMed Web of Science ®Google Scholar
• Duchow A, Chien C, Paul F, et al. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs. 2020;25(3):285–297.
   PubMed Web of Science ®Google Scholar
• Ma X, Kermode AG, Hu X, et al. Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy. Mult Scler Relat Disord. 2020;46:102522.
   PubMed Web of Science ®Google Scholar
• Palace J, Lin D-Y, Zeng D, et al. Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain. 2019;142(5):1310–1323.
   PubMedGoogle Scholar
• Molazadeh N, Filippatou AG, Vasileiou ES, et al. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. J Neuroimmunol. 2021;360:577702.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Specovius S, Zimmermann HG, et al. Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1068.
   PubMed Web of Science ®Google Scholar
• Motamedi S, Oertel FC, Yadav SK, et al. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e805.
   PubMed Web of Science ®Google Scholar
• Masuda H, Mori M, Hirano S, et al. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2022;93(1):32–40.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Harmel J, Zimmermann H, et al. Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology. 2020;94(4):e407–e18.
   PubMed Web of Science ®Google Scholar
• Goldschmidt C, Bermel RA. The calm between storms. serum biomarkers in assessing interattack astrocytopathy in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8:e988.
   PubMed Web of Science ®Google Scholar
• Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e134.
   PubMed Web of Science ®Google Scholar
• Eng LF, Vanderhaeghen JJ, Bignami A, et al. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971. 28(2): 351–354.
   PubMed Web of Science ®Google Scholar
• Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421–443.
   PubMed Web of Science ®Google Scholar
• Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121–130.
   PubMed Web of Science ®Google Scholar
• Li D, Liu X, Liu T, et al. Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes. Glia. 2020;68(5):878–897.
   PubMed Web of Science ®Google Scholar
• Brenner M, Johnson AB, Boespflug-Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001;27(1):117–120.
   PubMed Web of Science ®Google Scholar
• Prust M, Wang J, Morizono H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011;77(13):1287–1294.
   PubMed Web of Science ®Google Scholar
• Pekny M, Levéen P, Pekna M, et al. Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J. 1995;14(8):1590–1598.
   PubMed Web of Science ®Google Scholar
• Shibuki K, Gomi H, Chen L, et al. Deficient cerebellar long-term depression, impaired eyeblink conditioning, and normal motor coordination in GFAP mutant mice. Neuron. 1996;16(3):587–599.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35.
   PubMed Web of Science ®Google Scholar
• Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res. 2015;1600:17–31.
   PubMed Web of Science ®Google Scholar
• Escartin C, Galea E, Lakatos A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24(3):312–325.
   PubMed Web of Science ®Google Scholar
• Hart CG, Karimi-Abdolrezaee S. Recent insights on astrocyte mechanisms in CNS homeostasis, pathology, and repair. J Neurosci Res. 2021;99(10):2427–2462.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009;32(12):638–647.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158–172.
   PubMed Web of Science ®Google Scholar
• Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016–1024.
   PubMed Web of Science ®Google Scholar
• Rebelos E, Rissanen E, Bucci M, et al. Circulating neurofilament is linked with morbid obesity, renal function, and brain density. Sci Rep. 2022;12(1):7841.
   PubMed Web of Science ®Google Scholar
• Berry K, Asken BM, Grab JD, et al. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology. Alzheimers Dement (Amst). 2022;14(1):e12321.
   PubMedGoogle Scholar
• Nichols NR, Day JR, Laping NJ, et al. GFAP mRNA increases with age in rat and human brain. Neurobiol Aging. 1993;14(5):421–429.
   PubMed Web of Science ®Google Scholar
• Vagberg M, Norgren N, Dring A, et al. Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015;10(8):e0135886.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Lim YM, Kim S, et al. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol. 2020;7(6):992–1001.
   PubMed Web of Science ®Google Scholar
• Aktas O, Smith MA, Rees WA, et al. Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol. 2021. 89(5): 895–910.
   PubMed Web of Science ®Google Scholar
• Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18(1):105.
   PubMed Web of Science ®Google Scholar
• Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471–1483.
   PubMed Web of Science ®Google Scholar
• Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144(11):3505–3516.
   PubMedGoogle Scholar
• Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease. Alzheimers Dement. 2022;18(6):1141–1154.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019. 93(13): e1299–e311.
   PubMed Web of Science ®Google Scholar
• Sass D, Guedes VA, Smith EG, et al. Sex Differences in behavioral symptoms and the levels of circulating gfap, tau, and nfl in patients with traumatic brain injury. Front Pharmacol. 2021;12:746491.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Huss A, Kassubek J, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.
   PubMedGoogle Scholar
• de Kloet AD, Pioquinto DJ, Nguyen D, et al. Obesity induces neuroinflammation mediated by altered expression of the renin-angiotensin system in mouse forebrain nuclei. Physiol Behav. 2014;136:31–38.
   PubMed Web of Science ®Google Scholar
• Ehrlich S, Burghardt R, Weiss D, et al. Glial and neuronal damage markers in patients with anorexia nervosa. J Neural Transm (Vienna). 2008;115(6):921–927.
   PubMed Web of Science ®Google Scholar
• Bogoslovsky T, Wilson D, Chen Y, et al. Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid beta up to 90 Days after Traumatic Brain Injury. J Neurotrauma. 2017;34(1):66–73.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Hottenrott T, Morenas-Rodriguez E, et al. Glial activation markers in csf and serum from patients with primary progressive multiple sclerosis: potential of serum gfap as disease severity marker? Front Neurol. 2019;10:280.
   PubMed Web of Science ®Google Scholar
• Ayrignac X, Le Bars E, Duflos C, et al. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Sci Rep. 2020;10(1):10923.
   PubMedGoogle Scholar
• Alvarez E, Ritchie A, Nair K, et al. Evaluating the correlation between spinal fluid and blood levels of neurofilament light, gfap, tau, and uchl1: do we need a correction factor in evaluating blood levels? (4912). Neurology. 2020;94:4912.
   Web of Science ®Google Scholar
• Schulz I, Kruse N, Gera RG, et al. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders. Mov Disord. 2021;36(12):2874–2887.
   PubMed Web of Science ®Google Scholar
• van Ballegoij WJC, van de Stadt SIW, Huffnagel IC, et al. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. Ann Clin Transl Neurol. 2020;7(11):2127–2136.
   PubMed Web of Science ®Google Scholar
• Rezaii P, Grant G, Zeineh M, et al. Stability of blood biomarkers of traumatic brain injury. J Neurotrauma. 2019;36(16):2407–2416.
   PubMed Web of Science ®Google Scholar
• van Lierop Z, Verberk IMW, van Uffelen KWJ, et al. Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. Clin Chem Lab Med. 2022;60(6):842–850.
   PubMed Web of Science ®Google Scholar
• Papa L, Brophy GM, Welch RD, et al. Time Course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a Large Cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73(5):551–560.
   PubMed Web of Science ®Google Scholar
• Thelin EP, Zeiler FA, Ercole A, et al. Serial Sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review. Front Neurol. 2017;8:300.
   PubMed Web of Science ®Google Scholar
• Azizi S, Hier DB, Allen B, et al. A kinetic model for blood biomarker levels after mild traumatic brain injury. Front Neurol. 2021;12:668606.
   PubMed Web of Science ®Google Scholar
• Luoto TM, Raj R, Posti JP, et al. A Systematic Review of the Usefulness of Glial Fibrillary Acidic Protein for Predicting Acute Intracranial Lesions following Head Trauma. Front Neurol. 2017;8:652.
   PubMed Web of Science ®Google Scholar
• Bazarian JJ, Biberthaler P, Welch RD, et al. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018;17(9):782–789.
   PubMed Web of Science ®Google Scholar
• Czeiter E, Amrein K, Gravesteijn BY, et al. Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine. 2020;56:102785.
   PubMed Web of Science ®Google Scholar
• Yue JK, Yuh EL, Korley FK, et al. Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study. Lancet Neurol. 2019;18(10):953–961.
   PubMed Web of Science ®Google Scholar
• Heimfarth L, Passos FRS, Monteiro BS, et al. Serum glial fibrillary acidic protein is a body fluid biomarker: a valuable prognostic for neurological disease – a systematic review. Int Immunopharmacol. 2022;107:108624.
   PubMed Web of Science ®Google Scholar
• Sun M, Liu N, Xie Q, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;51:102870.
   PubMed Web of Science ®Google Scholar
• Hanson BA, Visvabharathy L, Ali ST, et al. Plasma biomarkers of neuropathogenesis in hospitalized patients with covid-19 and those with postacute sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm. 2022;9(3):e1151.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Sato DK, Callegaro D, de Haidar Jorge FM, et al. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol. 2014;76(2):305–309.
   PubMed Web of Science ®Google Scholar
• Kleerekooper I, Herbert MK, Kuiperij HB, et al. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. J Neurol Neurosurg Psychiatry. 2020;91(6):605–611.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Kim Y, Kim KH, et al. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. J Neuroinflammation. 2022;19(1):86.
   PubMed Web of Science ®Google Scholar
• Petzold A, Marignier R, Verbeek MM, et al. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry. 2011;82(4):467–469.
   PubMed Web of Science ®Google Scholar
• Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;75(3):208–216.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. London, UK: SAGE Publishing Ltd. 2010; vol. 16, p. 1443–1452
   Google Scholar
• Uzawa A, Mori M, Masuda S, et al. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2013;84(5):517–522.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang H, Li X, et al. CSF-S100B Is a potential candidate biomarker for neuromyelitis optica spectrum disorders. Biomed Res Int. 2018;2018:5381239.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang H, Li X, et al. Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6. Neuroimmunomodulation. 2018;25(4):215–224.
   PubMed Web of Science ®Google Scholar
• Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009;80(5):575–577.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181–183.
   PubMed Web of Science ®Google Scholar
• Fujii C, Tokuda T, Ishigami N, et al. Usefulness of serum S100B as a marker for the acute phase of aquaporin-4 autoimmune syndrome. Neurosci Lett. 2011;494(1):86–88.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Kim SH, Huh SY, et al. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. SAGE Publishing Ltd: London, UK. 2015; Vol. 21, p. 710–717.
   Google Scholar
• Yang X, Huang Q, Yang H, et al. Astrocytic damage in glial fibrillary acidic protein astrocytopathy during initial attack. Mult Scler Relat Disord. 2019;29:94–99.
   PubMed Web of Science ®Google Scholar
• Lee J, McKinney KQ, Pavlopoulos AJ, et al. Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis. Clin Chim Acta. 2016;462:118–126.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Michetti F, D’Ambrosi N, Toesca A, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2):168–187.
   PubMed Web of Science ®Google Scholar
• Kang H, Cao S, Chen T, et al. The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain. J Neuroimmunol. 2015;289:56–61.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401.
   PubMed Web of Science ®Google Scholar
• Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2021;19(2):220–232.
   PubMed Web of Science ®Google Scholar
• Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory mog-igg-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1100.
   PubMed Web of Science ®Google Scholar
• Zhang TX, Chen JS, Du C, et al. Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord. 2021;14:17562864211054952.
   Web of Science ®Google Scholar
• Yang S, Zhang C, Zhang TX, et al. A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. J Neurol. 2022. 10.1007/s00415-022-11364-9.
   Web of Science ®Google Scholar
• Hyun JW, Kim Y, Kim SY, et al. Investigating the presence of interattack astrocyte damage in neuromyelitis optica spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e965.
   PubMed Web of Science ®Google Scholar
• Liu C, Lu Y, Wang J, et al. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study. J Neurochem. 2021;159(5):913–922.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee EJ, Kim S, et al. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. SAGE Publishing Ltd: London, UK. 2022; Vol. 28, p. 512–521.
   Google Scholar
• Du L, Chang H, Xu W, et al. Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2021;52:102940.
   PubMed Web of Science ®Google Scholar
• Petzold A, Woodhall M, Khaleeli Z, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. J Neurol Neurosurg Psychiatry. 2019;90(9):1021–1026.
   PubMed Web of Science ®Google Scholar
• Storoni M, Petzold A, Plant GT. The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One. 2011;6(8):e23489.
   PubMed Web of Science ®Google Scholar
• Chang X, Huang W, Wang L, et al. Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front Immunol. 2021;12:647618.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee EJ, Kim S, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e708.
   PubMed Web of Science ®Google Scholar
• Aly L, Strauß EM, Feucht N, et al. Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. SAGE Publishing Ltd: London, UK ; 2021. p. 13524585211028831.
   Google Scholar
• Lin T-Y, Schindler P, Grittner U, et al. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022;67:104100.
   Google Scholar
• Storoni M, Verbeek MM, Illes Z, et al. Serum GFAP levels in optic neuropathies. J Neurol Sci. 2012;317(1–2):117–122.
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871–882.
   PubMed Web of Science ®Google Scholar
• Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246–257.
   PubMed Web of Science ®Google Scholar
• Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870–881.
   PubMed Web of Science ®Google Scholar
• Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–589.
   PubMed Web of Science ®Google Scholar
• Á J C-G, Forero L, Lozano-Soto E, et al. Cortical thickness and serum nfl explain cognitive dysfunction in newly diagnosed patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6). 10.1212/NXI.0000000000001074.
   Web of Science ®Google Scholar
• Mariotto S, Farinazzo A, M S, et al. serum neurofilament light chain in nmosd and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin. 2017;3(4):2055217317743098.
   Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383–392.
   PubMed Web of Science ®Google Scholar
• Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87(9):1005–1015.
   PubMed Web of Science ®Google Scholar
• Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137–145.
   PubMed Web of Science ®Google Scholar
• Prineas JW, Lee S. Multiple sclerosis: destruction and regeneration of astrocytes in acute lesions. J Neuropathol Exp Neurol. 2019;78(2):140–156.
   PubMed Web of Science ®Google Scholar
• Kessler RA, Mealy MA, Jimenez-Arango JA, et al. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study. Mult Scler Relat Disord. 2017;17:198–201.
   PubMed Web of Science ®Google Scholar
• Schmetzer O, Lakin E, Roediger B, et al. Anti-aquaporin 4 IgG Is not associated with any clinical disease characteristics in neuromyelitis optica spectrum disorder. Front Neurol. 2021;12:635419.
   PubMed Web of Science ®Google Scholar
• Tomizawa Y, Yokoyama K, Saiki S, et al. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability. J Int Med Res. 2012;40(4):1483–1491.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Masuda S, et al. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol. 2011;68(7):913–917.
   PubMedGoogle Scholar
• Wang Y, Zhu M, Liu C, et al. Blood brain barrier permeability could be a biomarker to predict severity of neuromyelitis optica spectrum disorders: a retrospective analysis. Front Neurol. 2018;9:648.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1–2):82–90.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Ruiz A, Richard C, et al. Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability. PLoS One. 2020;15(9):e0238301.
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Fujikawa S, Serizawa K, et al. New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1076.
   PubMed Web of Science ®Google Scholar
• Duchow A, Paul F, Bellmann-Strobl J. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opin Biol Ther. 2020;20(9):1061–1072.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Jang H, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflammat. 2021;8(2):e947.
   PubMed Web of Science ®Google Scholar
• Lin TY, Vitkova V, Asseyer S, et al. Increased serum neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1051.
   PubMed Web of Science ®Google Scholar